# TechMediaBreaks – Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) Prepares for Potential Fibromyalgia Drug Approval, Reports Q1 Results

Tonix Pharmaceuticals (NASDAQ: TNXP), a fully-integrated biopharmaceutical company, announced financial results for the first quarter of 2025 and reaffirmed its focus on the anticipated FDA decision for TNX-102 SL, a non-opioid analgesic for fibromyalgia, with a PDUFA goal date of Aug. 15. If approved, it would mark the first new drug class for fibromyalgia in more than 15 years. Tonix also highlighted progress across its pipeline, including positive Phase 1 data for TNX-1500 in kidney transplant rejection and strong preclinical results for TNX-801, a live-virus vaccine targeting mpox and smallpox. The company ended the quarter with $131.7 million in cash and cash equivalents and reported a net loss of $16.8 million on $2.4 million in product revenue.

 To view the full press release, visit https://ibn.fm/X5U44

 About Tonix Pharmaceuticals Holding Corp.

 Tonix is a fully integrated biopharmaceutical company focused on transforming therapies for pain management and modernizing solutions for public health challenges. Tonix’s priority is to submit a New Drug Application (“NDA”) to the U.S. Food and Drug Administration (“FDA”) this month for TNX-102 SL, a product candidate for which two statistically significant phase 3 studies have been completed for the management of fibromyalgia. TNX-102 SL was generally well tolerated in the phase 3 program. The FDA has granted Fast Track designation to TNX-102 SL for the management of fibromyalgia. TNX-102 SL is also being developed to treat acute stress reaction. Tonix recently announced that the U.S. Department of Defense (“DoD”), Defense Threat Reduction Agency (“DTRA”) awarded it a contract for up to $34 million over five years to develop TNX-4200, small molecule broad-spectrum antiviral agents targeting CD45 for the prevention or treatment of infections to improve the medical readiness of military personnel in biological threat environments. Tonix owns and operates a state-of-the art infectious disease research facility in Frederick, Maryland. The company’s Good Manufacturing Practice (“GMP”)-capable advanced manufacturing facility in Dartmouth, Maryland, was purpose-built to manufacture TNX-801, and the GMP suites are ready to be reactivated in case of a national or international emergency. Tonix’s development portfolio is focused on central nervous system (“CNS”) disorders. Tonix’s CNS portfolio includes TNX-1300 (cocaine esterase), a biologic in Phase 2 development designed to treat cocaine intoxication that has Breakthrough Therapy designation. Tonix’s immunology development portfolio consists of biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is a humanized monoclonal antibody targeting CD40-ligand (CD40L or CD154) being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases. Tonix also has product candidates in development in the areas of rare disease and infectious disease. Tonix Medicines, the company’s commercial subsidiary, markets Zembrace(R) SymTouch(R) (sumatriptan injection) 3 mg and Tosymra(R)(sumatriptan nasal spray) 10 mg for the treatment of acute migraine with or without aura in adults. For more information about the company, please visit www.TonixPharma.com.

 NOTE TO INVESTORS: The latest news and updates relating to TNXP are available in the company’s newsroom at https://ibn.fm/TNXP

 About TechMediaWire

 TechMediaWire (“TMW”) is a specialized communications platform with a focus on pioneering public and private companies driving the future of technology. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, TMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists, and the general public. By cutting through the overload of information in today’s market, TMW brings its clients unparalleled recognition and brand awareness. TMW is where breaking news, insightful content and actionable information converge.

 To receive SMS alerts from TechMediaWire, text “TECH” to 888-902-4192 (U.S. Mobile Phones Only)

 For more information, please visit https://www.TechMediaWire.com

 Please see full terms of use and disclaimers on the TechMediaWire website applicable to all content provided by TMW, wherever published or re-published: https://www.TechMediaWire.com/Disclaimer

 TechMediaWireAustin, Texaswww.TechMediaWire.com512.354.7000 OfficeEditor@TechMediaWire.com

 TechMediaWire is powered by IBN 

---

[Original/Source Press Release](https://rss.investorbrandnetwork.com/tmw/techmediabreaks-tonix-pharmaceuticals-holding-corp-nasdaq-tnxp-prepares-for-potential-fibromyalgia-drug-approval-reports-q1-results/)
                    

[Newsramp.com TLDR](https://newsramp.com/curated-news/tonix-pharmaceuticals-reports-q1-2025-results-and-progress-across-pipeline/1b94f18c3ff45c7732fd10c433b069ef) 

 



[Reddit Post](https://www.reddit.com/r/Business_NewsRamp/comments/1klmttc/tonix_pharmaceuticals_reports_q1_2025_results_and/) 



![Blockchain Registration](https://cdn.newsramp.app/ibn/qrcode/255/13/mielUxhT.webp)